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1,2 Telomere shortening, double-
stranded DNA damage, inﬂammation, and other forms of cell
stress all function as stimuli for cell senescence. Although
traditionally cellular senescence has been viewed as a protec-
tive response to cellular injury or disruption, the study of the
senescence-associated secretory phenotype (SASP) has
become increasingly implicated in the pathogenesis of hep-
atobiliary disease. Speciﬁcally, senescence has been hypothe-
sized to play a prominent role in cholangiopathies, including
primary sclerosing cholangitis (PSC), primary biliary cirrhosis
(PBC), cellular rejection (CR), and biliary atresia (BA). Over
time, the SASP may provide proinﬂammatory or other adverse
stimulus to hepatobiliary stem/progenitor cells, leading to the
observed disease phenotypes.3e5 This review summarizes
current evidence for the molecular mechanisms of cellular
senescence in the pathogenesis of select biliary diseases.
Cellular Senescence
First observed in 1965, human ﬁbroblasts were noted to
have a limited ability to replicate in culture.6 Senescentstigative Pathology.
.cells are metabolically active cells that often remain in situ
but no longer maintain proliferative activity. This devel-
opment is associated with morphological changes causing
the cells to appear large and ﬂat with characteristic nuclear
changes, including vacuolation.7e10 Two main tumor-
suppressor pathways, p53 and p16INK4a/pRB, have been
shown to regulate senescence responses.11 The expression
of associated cell cycle inhibitors, including p15INK4B,
p16INK4a, p21WAF1/Cip1, p53, and increased senescence-
associated b-galactosidase (SA-b-GAL) activity, is
commonly observed. In addition, the production of
senescence-associated heterochromatin foci and DNA damage
response proteins have all been used to aid in the identiﬁcation
Table 1 Summary of Effects of the Consequences on Various Cell Types
Cell type Consequences of senescence*
Hepatocytes Unclear, but senescence correlated with fibrosis stage13
Cholangiocytes Unclear, but senescence correlated with Banff grade in acute rejection14e16
Hepatic stellate cells Ameliorated fibrosis during acute liver damage via secretion of metalloproteinases17
Retinal pigment epithelial cells Disruption of division and migration and atrophy of retina in adult macular degeneration18
Fibroblasts Disrupted tissue structure locally via secretion of VEGF1
Melanocytes Reinforcing senescence via secretion of IL-6, IL-8, and PAI-119
*Senescence causes different effects in different tissues and cell types.
PAI, plasminogen activator inhibitor; VEGF, vascular endothelial growth factor.
Senescence in Biliary Injuryof senescent cells in association with the absence of replicative
markers (Ki-67 or thymidine analogue bromodeoxyuridine
in vitro).12 Overall, senescence has been shown to cause
different effects in different tissues and cell types (Table 1).
Correlating expression of these markers with disease states has
demonstrated the widespread prevalence of the senescent
states in hepatobiliary diseases.Replicative Senescence
Multiple effectors have been identiﬁed leading to the devel-
opment of senescence. Classically, replicative senescence de-
velops from telomere erosion associatedwith the accumulation
of replication cycles (aging) in the absence of corrective telo-
merase (Figure 1). The process of telomere erosion elicits a
DNA damage response, which acts to induce the expression of
g-H2Ax (a phosphorylated histone variant of H2Ax) and the
DNA damage response proteins p53-binding protein 1, nibrin,
and mediator of DNA damage checkpoint protein 1. DNA
damage kinases ataxia telangiectasia mutated and ataxia tel-
angiectasia and Rad3-related protein are subsequentlySASP
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The American Journal of Pathology - ajp.amjpathol.orgactivated and, in turn, activate checkpoint kinases 1 and 2.20,21
The resultant signal cascade leads to differential expression of
p53 isoforms, and has been linked directly to senescent phe-
notypes, although the process, including breakpoints between
apoptosis and senescence, remains incompletely understood,
with some role of NF-kB in its regulation.22,23 In cholestatic
liver disease, the role of age-related telomere erosion does not
seem prominent. In a study of telomeres using quantitative
ﬂuorescent in situ hybridization (Q-FISH) and conﬁrmed by
Southern blot analysis from 73 normal liver samples, chol-
angiocytes and hepatocytes were shown to maintain their
telomere lengths independent of age with only Kupffer and
stellate cells, demonstrating age-related attrition.24Premature Senescence
Numerous other mechanisms independent of replicative
senescence have been identiﬁed as pathways of so-called
premature senescence, including chromatin instability, DNA
damage, dysfunctional telomeres, oncogenic mutations,
overexpression of cell cycle inhibitors, and stress signalsr 
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 Repair /
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Figure 1 The senescence-associated secretory
phenotype (SASP) during aging, cancer develop-
ment, and progression. Cellular senescence has
dual effects on human health during the pro-
gression of aging and various human disorders.
The beneﬁcial effects include tumor suppression
and tissue repair after injury; the deleterious ef-
fects include tumor and aging promotion that
involve several key SASP molecules, including
IL-6, IL-8, matrix metalloproteinases (MMPs), and
speciﬁc miRNAs.
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Figure 2 Overview of senescence. Various
factors, such as telomeric dysfunction, DNA dam-
age, oncogenic activation, and oxidative stress,
induce senescence in division competent cells. On
becoming senescent, the cell and its nucleus
become enlarged and begin to express p16INK4a,
p21WAF1/Cip1, and senescence-associated b-galac-
tosidase (SA-b-GAL). Senescent cells present a
large ﬂattened morphology and build up a SA-b-
GAL activity that distinguishes them from most
quiescent cells.
Meng et al(Figure 2). Oncogenic-induced senescence has been
commonly characterized in vitro using mutant H-RasV12, an
oncogene, to induce cell cycle arrest signals by activating
p53 and p16INK4A/pRB pathways.25 p53 contributes to
cellular senescence by transactivating genes that block
cellular proliferation, including the p21/Cip1/WAF1 cyclin-
dependent kinase inhibitor and miR-34 class of miRNAs.26
Similarly, loss of tumor suppressors (phosphatase and tensin
homolog and neuroﬁbromin 1) has been shown to induce
premature senescent pathways.27,28 Although our under-
standing of DNA damageerelated senescence provides new
insights into these molecular processes, stress-induced
senescence is currently more a focal point for research on
the pathobiology of cholangiopathies. In vitro, stress-
induced senescence has been modeled with alterations in
culture medium, growth factors, and oxidative stress in
various human cell lines.29e32 In mouse cholangiocytes,
proinﬂammatory cytokines, such as tumor necrosis factor a,
interferons b and g, have been used to generate reactive
oxygen species and were shown to induce senescence via
the p53/p21WAF1/Cip1 pathway.33 The evidence linking
autoinﬂammatory cholangiopathies to this pathway will be
discussed later.Potential Mechanisms of Senescence-Related
Human Diseases
Senescence-Associated Secretory Phenotype
Senescent cells exhibit altered gene expression and promi-
nently secrete cytokines (eg, IL-1 and IL-6), chemokines
(eg, IL-8, CXCL-1, and CXCL-2), insulin-like growth
factorebinding proteins (IGFBPs), and several other factors,604including matrix metalloproteinases, serine proteases, and
proinﬂammatory colony-stimulating factors. These soluble
signaling factors are referred to as the SASP.34 Acting via
paracrine and autocrine mechanisms, these proteins alter the
microenvironment of the cells, which may lead to a
disruption of tissue structure and function (Figure 3).
Although SASP has attracted interest for its potential
pathological role in many human diseases, the biological
function of SASP as a regulatory mechanism in tumor
suppression and other areas remains incompletely under-
stood. Evidence has emerged related to the antiﬁbrotic
effects of SASP in the setting of acute liver injury. As
hepatic stellate cells proliferate and secrete extracellular
matrix (ECM) components and undergo senescence to
develop SASP (Figure 4), they secrete metalloproteinases
and other proinﬂammatory molecules that digest the ECM
proteins counterbalancing the initial ﬁbrotic response.35
Because senescence has also been reported in chronic bile
duct inﬂammation in the setting of primary biliary cirrhosis
and primary sclerosing cholangitis,36 and cholangiocytes in
PSC liver exhibit increased expression of SASP compo-
nents,15 the senescence program may also limit the ﬁbro-
genic response to cholestatic liver injury through the similar
hepatic stellate celldrelated mechanisms.
Induction of Senescence in Nearby Cells
The ability of SASP to propagate senescence through pos-
itive feedback has been hypothesized to potentially be a
pathological mechanism in cholangiopathies. To date, the
evidence for this effect remains limited. The observation of
clustered expression of p16INK4a in nevi has led to the
hypothesis that senescent cells secrete senescence-inducingajp.amjpathol.org - The American Journal of Pathology
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Figure 3 Formation of senescence-associated
secretory phenotype (SASP). Senescent cells/
cholangiocytes display different phenotypes from
quiescent or terminally differentiated cells (nondi-
viding), whereas the deﬁnite feature of the senescent
phenotype is notably deﬁned. The signiﬁcant markers
of senescent cells/cholangiocytes include an essen-
tially irreversible growth arrest; expression of
senescence-associated b-galactosidase (SA-b-GAL)
and p16INK4a; nuclear foci containing DNA damage
response proteins (DNA-SCARS/TIF) or senescence-
associated heterochromatin foci (SAHF); and robust
secretion of various growth factors, cytokines (proin-
ﬂammatory), proteases, and other proteins, such as
SASP. Proinﬂammatory SASP mediators (C-X-C che-
mokine receptor 2, IL-6, and IL-6 receptor) can rein-
force cellular senescence in an autocrine or paracrine
manner. The secretion of SASP is the most signiﬁcant
of these effects because it turns senescent cells/
cholangiocytes into a proinﬂammatory state that has
the ability to promote disease progression. SCARS,
segments with chromatin alterations reinforcing
senescence; TIF, telomere dysfunction-induced foci.
Senescence in Biliary Injuryagents that act on other cells locally.37 Subsequently, in human
melanoma cell lines, high levels of IGFBP P-rP1 (IGFBP-rP1,
previously known as IGFBP7 and mac25) inhibit BRAF-
MEK-ERK oncogene signaling and activate senescence or
apoptotic pathways.38 As discussed later, overexpression of
IGFBP-rP1 has also been observed in BA. However, its exact
function in the setting of the disease remains unclear. IGFBP-5
has also been implicated as a protein, which may act locally to
induce senescence. Human umbilical endothelial cells treated
with exogenous recombinant human IGFBP-5 were found to
increase expression of p53 and p21 and decrease proliferation
compared to untreated controls.39
Depletion of Progenitor Cell Populations
The potential pathological link between senescence and the
depletion of progenitor cells is perhaps theoretically more
obvious. The antiproliferative properties of senescence can
be detrimental to essential functions of progenitor cell pop-
ulations, which are crucial to tissue repair and regeneration in
numerous organs, particularly the liver. It is possible that as
injury or other stimuli deplete these populations, it interferes
with proper tissue function. Some of the most direct evidence
for this pathological mechanism comes from research on
cardiac anthracycline toxicity using a rat model. Treatment of
mice with doxorubicin led to expansion of a p16INK4a-
positive cardiac stem cell population exhibiting irreversible
growth arrest, and this population was signiﬁcantly associ-
ated with left ventricular dysfunction. By using intra-
myocardial injections of syngeneic cardiac stem cells,
researchers were able to rescue the cardiac function of the
treated animals, which led to signiﬁcantly improved survival
compared to untreated controls.40 The functional role of a
strong cellular senescence inducer, the homeobox transcrip-
tion factor prospero homeobox protein 1 (Prox1), has beenThe American Journal of Pathology - ajp.amjpathol.orgrecently clariﬁed in liver progenitors.41 Prox1 depletion in
bipotent hepatoblasts signiﬁcantly decreased the expression
of multiple hepatocyte genes and led to defective hepatocyte
morphogenesis. Consequently, abnormal epithelial structures
expressing hepatocyte and cholangiocyte markers or resem-
bling ectopic bile ducts developed in the Prox1-deﬁcient liver
parenchyma. Nevertheless, excessive commitment of hep-
atoblasts into cholangiocytes, premature intrahepatic bile
duct morphogenesis, and biliary hyperplasia occurred in
periportal areas of Prox1-deﬁcient livers.41 Certainly, the
crucial role of liver progenitor cells could suggest that there
may be some contribution of this model in hepatobiliary
disease as well.
Cholangiopathies
Biliary Atresia
BA is a progressive, ﬁbro-obliterative disease of the extra-
hepatic biliary tree that represents the most common cause
of pediatric liver transplantation. Even with early Kasai
hepatoportoenterostomy, liver transplantation remains
necessary for 60% to 80% of patients, and without trans-
plant, the 5-year survival is an unfortunate 60%.42e44 The
pathophysiology of this disease remains unknown, although
a combination of viral, toxic, genetic, and immunological
etiologies have been generally considered.
Interestingly, senescence markers have been observed in
affected pediatric patients. In two patients with cirrhosis sec-
ondary to BA, p53 and SA-b-GAL were seen expressed in
nodular hepatocytes, canals of Hering, and cholangioles with
an absent expression of p16 or p21.45 These observations
correlate with the results of a genome-wide gene expression
analysis of normal, diseased control, and end-stage BA livers,
which found strong expression of IGFBP-rP1 compared to the605
Figure 4 Recovery effect of hepatic stellate
cells drives the senescence-associated secretory
phenotype (SASP) during liver ﬁbrosis. The
secretion of SASP by activated stellate cells can
prevent further proliferation of extracellular ma-
trix (ECM)-producing cells, promote ECM degra-
dation, and accelerate clearance of activated
hepatic stellate cells from the site of liver injury/
ﬁbrosis. COL1A1, type I collagen; COL1A2,
collagen 1 chain type II; CTGF, connective tissue
growth factor; MMP, matrix metalloproteinases;
PDF, pigment-dispersing factor; ROS, reactive
oxygen species; TGF, transforming growth factor;
TIMP, tissue inhibitor of metalloproteinases.
Meng et alnormal and non-BA diseased controls. Previously, IGFBP-rP1
has been shown to be up-regulated in various cell lines with
senescent phenotypes and has shown to be a p53-responsive
gene.46,47 Although the data are limited, taken together,
these ﬁndings may suggest a possible mechanism for senes-
cence of cholangiocytes in BA.
Although previously there have been little data involving
telomere dysfunction as a mechanism leading to BA, a study
by Sanada et al48 measured hepatocyte telomeres using
Q-FISH and showed preserved telomere length, but normal-
ized telomere/centromere ratios, being markedly reduced
compared to healthy controls. Whether these ﬁndings repre-
sent a true cause or consequence of the BA remains unclear.
Previously, estimations of hepatocyte telomere lengths using
Q-FISH in patients with cirrhosis from chronic viral hepatitis,
autoimmune hepatitis, primary sclerosing cholangitis, primary
biliary cirrhosis, and alcoholic liver disease have found that
telomere length correlates to Child-Pugh score independent of
associated disease.49 Although the role of telomere dysfunc-
tion in BA remains unclear, these studies suggest that hepa-
tocyte telomere length may have some potential role as an
adjunct biomarker to clinical scoring models of cirrhosis, such
as pediatric end-stage liver disease, model for end-stage liver
disease, and Child-Pugh in certain diseases.
Primary Sclerosing Cholangitis
PSC is an idiopathic, autoinﬂammatory disorder characterized
by ﬁbrosis, stricturing, and obliteration of medium and large
ducts throughout the biliary epithelium. This incurable disease
has a prominent associationwith inﬂammatory bowel disease in
70% of patients, particularly ulcerative colitis, and its progres-
sive nature leads to complications, including cholestasis, he-
patic failure, and cholangiocarcinoma.50 Median survival in the
absence of liver transplant is between 10 and 12 years.51,52
The role of cell senescence in PSC remains an emerging
ﬁeld of research. Cholangiocytes in PSC have been shown to
have increased expression of SA-b-GAL, p16INK4a, and606p21WAF1.53 We have demonstrated that two cellular senes-
cence markers, plasminogen activator inhibitor-1 and p57,
are signiﬁcantly increased in isolated cholangiocytes from
MDR2 knockout mice, which develop periportal ﬁbrosis
similar to human PSC (unpublished data). Plasminogen
activator inhibitor-1 is an essential mediator of replicative
senescence in vitro and is one of the biochemical ﬁngerprints
of senescence in vivo.54 The p57 overexpression induced
cellular senescence through cell cycle arrest in the G1
phase.55 It has been demonstrated that p57 is involved in
hepatocyte growth arrest at two distinct points during liver
development: the perinatal period and the postnatal transition
to a quiescent adult hepatocyte phenotype.56 Recently,
Tabibian et al15 demonstrated increased expression of
g-H2Ax, a marker of DNA damage and up-regulation of
SASP markers IL-6, IL-8, chemokine ligand 2, and plas-
minogen activator inhibitor-1 in diseased samples. Corollary
to these ﬁndings, by using the lipopolysaccharide inﬂam-
matory stress model, they reproduced cholangiocyte
senescence-inducing expression of SASP markers and
bystander cholangiocyte senescence. Furthermore, their
study showed signiﬁcantly increased expression of N-Ras
protein colocalization with activated RAS in PSC, which was
absent in PBC, hepatitis C, or control samples. The data build
on their previous work suggesting that N-Ras protein medi-
ates lipopolysaccharide-induced inﬂammation, further sup-
porting a potential role for N-Ras signaling in the
pathogenesis of PSC, adding a molecular mechanism to our
understanding of PSC as an inﬂammatory disease.57
One recent study has characterized and identiﬁed
phenotypic and signaling features of isolated PSC patient-
derived cholangiocytes.58 The cholangiocytes from stage
4 PSC patient liver explants were isolated by dissection,
differential ﬁltration, and immune-magnetic bead separa-
tion. The proportion of cholangiocytes staining positive
for senescence-associated b-galactosidase was found to be
much higher in PSC cholangiocytes compared with
cultured normal human cholangiocytes (48% versus 5%;ajp.amjpathol.org - The American Journal of Pathology
Senescence in Biliary InjuryP < 0.01).58 Interestingly, by using Q-FISH, telomere
length in the cholangiocytes of nine PSC samples was
found to be maintained compared to normal controls.15
Adjacent hepatocyte telomere length was not reported.
If the data from Wiemann et al49 on shortened hepatocyte
telomeres in PSCs are substantiated, a complex interac-
tion of senescent pathways could be involved in the
pathogenesis of this disease. Certainly, differences in
stages of liver disease may play a role, but further clari-
ﬁcation of the data on the telomere length of hepatocytes
and cholangiocytes in PSCs may be helpful.
Cellular Rejection
Acute CR has historically been associated with a progressive,
obliterative cholangiopathy. Histopathology shows a non-
suppurative cholangitis of the interlobular bile ducts with
cholangiocytes exhibiting cellular and nuclear enlargement,
multinucleation with uneven nuclear spacing, and thickening
of the basement membrane.59 In recent years with more
aggressive immunosuppression, the rate of CR has decreased
from 60% to 70% to 15% to 20% in graft recipients, with
ductopenia becoming even rarer.60 Despite therapeutic ad-
vances, CR remains a signiﬁcant cause of morbidity and cost
in liver transplant.
Even in early stages of CR, senescence has been observed
with absent proliferation of cholangiocytes despite their
stereotypical proliferative response to injury.61 The number
of p21WAF1/Cip1-positive cholangiocytes has been shown to
correlate with the Banff grade of acute rejection and declines
with treatment.62,63 Previously, it has been observed that
patients with failed allografts who had received cyclosporine
had more ductopenia than patients who had received tacro-
limus.64 Interestingly in other epithelial tissues, cyclosporine,
but not tacrolimus, has been shown to augment transforming
growth factor-b expression, which is known to induce
p21WAF1/Cip1 expression.65 Building on these ﬁndings, Brain
et al14 presented observational data on S100A4 expression in
CR and in an in vitro model that described dedifferentiation
driven by transforming growth factor-b2. Given the diverse
expression of S100A4, the precise implications of this work
are uncertain, yet intriguing.
Primary Biliary Cirrhosis
PBC is a progressive, autoimmune cholangiopathy involving
the small intrahepatic bile ducts. The disease tends to affect
women >40 years who may present with symptoms of
cholestasis, ﬁbrotic biliary lesions, and hepatomegaly.66,67
Over time if untreated, the sustained loss of bile duct
epithelial cells in PBC leads to cirrhosis and liver failure.
Serum antimitochondrial antibodies can be detected in the
90% of cases. These antibodies target the E2 and E3BP
subunits of the pyruvate dehydrogenase complex (PDC-E2
and PDC-E3BP).68,69 However, their involvement in the
pathogenesis of PBC has been uncertain.The American Journal of Pathology - ajp.amjpathol.orgSasaki et al53 have led research on the role of cellular
senescence in pathogenesis of PBC. The authors have
shown that PBC cholangiocytes exhibit senescence markers
SA-b-GAL, p16INK4, and p21WAF1/Cip far more frequently
than normal and viral hepatitis controls and observed the
increased presence of inﬁltrating myeloperoxidase-positive
inﬂammatory cells in PBC.53 The role of the inﬂammatory
cells remains unclear, but it suggests that oxidative
stresseinduced senescence may contribute to the patho-
genesis of PBC. Examining telomere length using Q-FISH,
they demonstrated that diseased small bile ducts and duct-
ules in PBC compared with normal-appearing bile ducts in
PBC, chronic viral hepatitis, and normal livers had signiﬁ-
cantly shorter telomeres, although the role of telomere
length in PBC is unknown.
More interestingly, autophagy, the lysosomal pathway
involving the catabolism of cellular components, has been
identiﬁed as a necessary component to the activation of cell
senescence.70 Sasaki et al71 showed that senescent PBC
cholangiocytes accumulated markers of autophagy, including
microtubule-associated proteins-light chain 3b, cathepsin D,
and lysosome-associated membrane protein-1. They further
showed aggregation of p62 sequestosome-1, a speciﬁc
marker for autophagy, in diseased small bile ducts, suggest-
ing some impairment of autophagy in PBC.2,70e72 Subse-
quently, the group has shown colocalization of mitochondrial
antigen PDC-E2 with autophagy marker light chain 3b and
increased in vitro cell surface expression of PDC-E2 in
cultured biliary epithelial cells on exposure to various
stresses.73 Taken together, these ﬁndings provide insight into
the relationship between autophagy, the expression of mito-
chondrial antigens, and autoimmunity in PBC. The exact
mechanisms behind this pathological interaction remain un-
clear, but certainly this work suggests further understanding
of the pathways related to senescence, particularly autophagy,
may yield new insights in the development of biliary disease.
Conclusion and Perspectives
Cellular senescence is linked to the development of various
human diseases, and its role in biliary disease remains to be
completely elucidated. Even as recent data suggest new
questions related to the mechanisms of senescence in the
development of cholangiopathies, the role cellular senes-
cence plays in the regulation of biliary growth, injury, and
response to injury continues to expand our understanding of
biliary disease and hopefully, in the future, yield new op-
portunities for targeted therapies.
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